Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 751Pancreatic Neoplasms 665Stomach Neoplasms 387Carcinoma, Non-Small-Cell Lung 375Carcinoma, Hepatocellular 368Breast Neoplasms 316Colonic Neoplasms 279Ovarian Neoplasms 260Neoplasms 250Esophageal Neoplasms 237Neoplasm Metastasis 215Rectal Neoplasms 202Melanoma 195Lung Neoplasms 193Liver Neoplasms 180Squamous Cell Carcinoma of Head and Neck 150Carcinoma, Renal Cell 146Head and Neck Neoplasms 124Prostatic Neoplasms 123Triple Negative Breast Neoplasms 109Uterine Cervical Neoplasms 106Urinary Bladder Neoplasms 106Cholangiocarcinoma 104Endometrial Neoplasms 101Sarcoma 99Small Cell Lung Carcinoma 74Gastrointestinal Neoplasms 73Esophageal Squamous Cell Carcinoma 68Kidney Neoplasms 63Carcinoma, Transitional Cell 60

Interventions

veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hereditary Breast and Ovarian Cancer Syndrome × Gastrointestinal × Clear all
NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡